118 related articles for article (PubMed ID: 24637536)
1. Ganglioside disialosyl globopentaosylceramide is an independent predictor of PSA recurrence-free survival following radical prostatectomy.
Shimada S; Ito A; Kawasaki Y; Kakoi N; Taima T; Mitsuzuka K; Watanabe M; Saito S; Arai Y
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):199-205. PubMed ID: 24637536
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of ganglioside DSGb5 expression in renal cell carcinoma.
Itoh J; Ito A; Shimada S; Kawasaki Y; Kakoi N; Saito H; Mitsuzuka K; Watanabe M; Satoh M; Saito S; Arai Y
Glycoconj J; 2017 Apr; 34(2):267-273. PubMed ID: 28205070
[TBL] [Abstract][Full Text] [Related]
3. Expression of Ganglioside Disialosyl Globopentaosyl Ceramide in Prostate Biopsy Specimens as a Predictive Marker for Recurrence after Radical Prostatectomy.
Sato M; Shimada S; Watanabe M; Kawasaki Y; Sato T; Morozumi K; Mitsuzuka K; Ito A
Tohoku J Exp Med; 2020 Sep; 252(1):1-8. PubMed ID: 32814720
[TBL] [Abstract][Full Text] [Related]
4. Ganglioside, disialosyl globopentaosylceramide (DSGb5), enhances the migration of renal cell carcinoma cells.
Kawasaki Y; Ito A; Kakoi N; Shimada S; Itoh J; Mitsuzuka K; Arai Y
Tohoku J Exp Med; 2015 May; 236(1):1-7. PubMed ID: 25864532
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.
Lepor H; Cheli CD; Thiel RP; Taneja SS; Laze J; Chan DW; Sokoll LJ; Mangold L; Partin AW
BJU Int; 2012 Jun; 109(12):1770-5. PubMed ID: 21992499
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
Inoue H; Nishimura K; Yamaguchi S; Nonomura N; Hara T
Int J Clin Oncol; 2015 Feb; 20(1):171-5. PubMed ID: 24652165
[TBL] [Abstract][Full Text] [Related]
8. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells.
Kawasaki Y; Ito A; Withers DA; Taima T; Kakoi N; Saito S; Arai Y
Glycobiology; 2010 Nov; 20(11):1373-9. PubMed ID: 20663960
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody (5F3) defining renal cell carcinoma-associated antigen disialosyl globopentaosylceramide (V3NeuAcIV6NeuAcGb5), and distribution pattern of the antigen in tumor and normal tissues.
Ito A; Saito S; Masuko T; Oh-Eda M; Matsuura T; Satoh M; Nejad FM; Enomoto T; Orikasa S; Hakomori SI
Glycoconj J; 2001 Jun; 18(6):475-85. PubMed ID: 12084983
[TBL] [Abstract][Full Text] [Related]
11. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
13. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
14. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
15. Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue volume in patients undergoing radical prostatectomy: a new predictor of biochemical recurrence in localized or locally advanced prostate cancer.
Ku JH; Moon KC; Cho SY; Kwak C; Kim HH
Asian J Androl; 2011 Mar; 13(2):248-53. PubMed ID: 21102474
[TBL] [Abstract][Full Text] [Related]
16. Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.
Mathieu R; Shariat SF; Seitz C; Karakiewicz PI; Fajkovic H; Sun M; Lotan Y; Scherr DS; Tewari A; Montorsi F; Briganti A; Rouprêt M; Lucca I; Margulis V; Rink M; Kluth LA; Rieken M; Bachman A; Xylinas E; Robinson BD; Bensalah K; Margreiter M
World J Urol; 2015 Aug; 33(8):1165-71. PubMed ID: 25344896
[TBL] [Abstract][Full Text] [Related]
17. Biochemical disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/mL) and clinically localized prostate cancer after radical prostatectomy.
Brandli DW; Koch MO; Foster RS; Bihrle R; Gardner TA
BJU Int; 2003 Jul; 92(1):19-22; discussion 22-3. PubMed ID: 12823376
[TBL] [Abstract][Full Text] [Related]
18. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
19. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.
Ploussard G; Salomon L; Allory Y; Terry S; Vordos D; Hoznek A; Abbou CC; Vacherot F; de la Taille A
BJU Int; 2010 Jul; 106(1):86-90. PubMed ID: 19930177
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
